HCC
ASMB icon

Hirtle Callaghan & Co’s Assembly Biosciences ASMB Stock Holding History

Hirtle Callaghan & Co’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3
Closed -$1K – 642
2013
Q4 		$1K Hold
3
– – ﹤0.01% 569
2013
Q3 		$0 Hold
3
– – ﹤0.01% 626
2013
Q2 		$0 Buy
+3
New +$470 ﹤0.01% 62

Other funds holding ASMB

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hirtle Callaghan & Co's ASMB Position: Q1 2014 in Review

Hirtle Callaghan & Co sold out of Assembly Biosciences (ASMB) in Q1 2014, closing a stake of 3 shares — an estimated $1K sold.

Hirtle Callaghan & Co first reported a position in ASMB in Q2 2013 and held it in 3 quarters. The position peaked at $1K in Q4 2013. 28 funds tracked by Wall St. Rank hold ASMB as of Q1 2014.

  • Hirtle Callaghan & Co reported no remaining Assembly Biosciences position as of Q1 2014 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 3 Assembly Biosciences shares in Q1 2014, an estimated $1K.
  • Hirtle Callaghan & Co first reported a position in Assembly Biosciences in Q2 2013 and held it in 3 quarters.
  • Hirtle Callaghan & Co's Assembly Biosciences position peaked at $1K in Q4 2013.
  • 28 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2014.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2014, filed 2 May 2014.